Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change ...

Olivia Munn and her mothers breast cancer journey highlights the importance of using breast cancer risk assessment tools like ...

The global HER2+ gastric cancer market is experiencing significant growth, driven by the rising incidence of gastric cancer and increased healthcare investments. HER2-positive gastric cancer, ...

A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...

Olivia Munn shares how a risk assessment test led to her mom’s early HER2 breast cancer diagnosis Read ahead to know why risk ...

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

HER2 tumor marker tests are used to determine whether breast cancer is HER2 positive or negative. A person is a candidate for HER2 testing if the cancer is invasive, metastatic, and/or recurrent.

Preliminary results of an observational clinical trial underway at Roswell Park Comprehensive Cancer Center are shedding ...